戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 gonist), or methoctramine (a selective M2/M4 muscarinic receptor antagonist).
2 of scopolamine, a nonselective acetylcholine muscarinic receptor antagonist.
3 either saline or scopolamine, a nonselective muscarinic receptor antagonist.
4 ed in the presence or absence of a selective muscarinic receptor antagonist.
5 letely blocked by scopolamine (10 microM), a muscarinic receptor antagonist.
6 nd can be reliably and completely blocked by muscarinic receptor antagonists.
7  rendered ineffective by either nicotinic or muscarinic receptor antagonists.
8 r subtypes prompted development of selective muscarinic receptor antagonists.
9 drome produced by systemic administration of muscarinic receptor antagonists.
10  and characterized as potential m1 selective muscarinic receptor antagonists.
11                                       The M3 muscarinic receptor antagonist 4-DAMP effectively revers
12       Pretreatment with pertussis toxin or a muscarinic receptor antagonist abolished agonist-induced
13                                              Muscarinic receptor antagonists and beta-adrenoceptor ag
14 ntribute to a rationale for a combination of muscarinic receptor antagonists and beta-adrenoceptor ag
15  on one or both of the aromatic rings of the muscarinic receptor antagonist aprophen [(N,N-diethylami
16                            The novel inhaled muscarinic receptor antagonists are potentially useful t
17  of long-acting beta(2) agonists/long-acting muscarinic receptor antagonists as the preferred treatme
18            These effects were blocked by the muscarinic receptor antagonist atropine (1 uM).
19 endent manner by local administration of the muscarinic receptor antagonist atropine (30 and 60 micro
20  and with the iontophoretically administered muscarinic receptor antagonist atropine (400 microA cm-2
21  by intrathecal injection of the cholinergic muscarinic receptor antagonist atropine, but was not aff
22 d by SR141716 but remained unaffected by the muscarinic receptor antagonist atropine.
23 hol and could be completely inhibited by the muscarinic receptor antagonist atropine.
24 e neuropathic rats, the inhibitory effect of muscarinic receptor antagonists (atropine and scopolamin
25                                          The muscarinic receptor antagonist, atropine (100 microM), d
26             When the competition between the muscarinic receptor antagonist, atropine, and [3H]N-meth
27                       Here, we show that the muscarinic receptor antagonist, atropine, eliminated the
28                                          The muscarinic receptor antagonist, atropine, significantly
29                            Nicotinic but not muscarinic receptor antagonists block allergen- or nicot
30 (NMDA receptor antagonist), and scopolamine (muscarinic receptor antagonist) blocked rapid plastic ch
31 harmacological treatment involves the use of muscarinic receptor antagonists, but their therapeutic e
32 nt pharmacological treatment involves use of muscarinic receptor antagonists, but their therapeutic e
33 r hand, the microinjection of scopolamine (a muscarinic receptor antagonist) did not block the induct
34 a blood-brain barrier-impermeant cholinergic muscarinic receptor antagonist, evoked results similar t
35   NMDA, metabotropic glutamate, GABA(B), and muscarinic receptor antagonists, in contrast, are mainly
36  treatment with solifenacin, an FDA-approved muscarinic receptor antagonist, increased oligodendrocyt
37 haled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and long-acting b
38 nd used as a renewable biological target for muscarinic receptor antagonist ligands.
39 by angiotensin type 1 (AT1) or acetylcholine muscarinic receptor antagonists (losartan and atropine).
40 e, ACh-induced rebound was blocked by the M2 muscarinic receptor antagonist methoctramine but not by
41 tric oxide synthase (nNOS) inhibitors and M4 muscarinic receptor antagonists only after injury.
42 0, 0.03, or 0.1 mg/kg, intraperitoneally), a muscarinic receptor antagonist, or mecamylamine (0, 0.75
43                                       The M1 muscarinic receptor antagonist pirenzepine dose dependen
44 ated, 384-well format, by characterizing the muscarinic receptor antagonists pirenzepine and atropine
45                             In addition, two muscarinic receptor antagonists (pirenzepine and atropin
46 Blockade of cholinergic neurotransmission by muscarinic receptor antagonists produces profound defici
47 es report that scopolamine, an acetylcholine muscarinic receptor antagonist, produces rapid antidepre
48                 Scopolamine, a non-selective muscarinic receptor antagonist, produces rapid antidepre
49      As a group, the carbaphens retained the muscarinic receptor antagonist properties of aprophen bu
50                               In addition, a muscarinic receptor antagonist reduces LID.
51 rough local iontophoretic application of the muscarinic receptor antagonist scopolamine and the nicot
52 formance was facilitated by the nonselective muscarinic receptor antagonist scopolamine as well as th
53              Pretreatment with the selective muscarinic receptor antagonist scopolamine blocked the c
54 clarative memory by infusing the cholinergic muscarinic receptor antagonist scopolamine into the rat
55 ction would improve depressive symptoms, the muscarinic receptor antagonist scopolamine manifested an
56 ing iontophoretic application of the general muscarinic receptor antagonist scopolamine with single-c
57               Systemic administration of the muscarinic receptor antagonist, scopolamine, augments, w
58 n-primate study exploring the effects of the muscarinic receptor antagonist solifenacin on anxious be
59 35SO4 as a label for secreted mucus, and the muscarinic receptor antagonists telenzepine for the M1 r
60                          Atropine (ATR) is a muscarinic receptor antagonist that blocks the post-syna
61        Trospium is a peripherally restricted muscarinic receptor antagonist that reduces peripheral c
62         This study tests the hypothesis that muscarinic receptor antagonist therapy with tiotropium b
63  studies have suggested that the long-acting muscarinic receptor antagonist tiotropium, a drug widely
64                   In search of a backup M(2) muscarinic receptor antagonist to the previously reporte
65 arXT combines xanomeline with the peripheral muscarinic receptor antagonist trospium chloride with th
66  xanomeline with the peripherally restricted muscarinic receptor antagonist trospium chloride with th
67                                            A muscarinic receptor antagonist was identified as top can
68 ent and the ratio of those using long-acting muscarinic receptor antagonist were higher than those in
69 herapy with tiotropium bromide, an M1 and M3 muscarinic receptor antagonist, will decrease the airway